102
Differentiated CD38-CD3 Bionic to Treat AML
City of Hope
Antibody
Oncology
Hit To Lead or Lead Optimization
• Inventors have developed bispecific molecules (“bionics”) directed against CD38 and CD3 to target CD38-overexpressing cancers such as AML.
• The molecules show significant advantages over conventional daratumumab therapy including that
– they kill AML cells w/o affecting human peripheral blood viability
– they specifically kill CD38+ cancer cells
– They engage with CD4 positive cells, leading to high levels of IFN-g production
– Local IFN-g induced CD38 on leukemic stem cells and their subsequent destruction
– They do not kill human NK or T cells in co-culture assays
– They exhibit favorable therapeutic/manufacturing properties extensive biochemical, in vitro and in vivo data (multiple animal models) are available under confidentiality
• The bionic technology is a platform that can be expanded to other antigens/bispecifics.
WO2022094147A1
